Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ATD-001
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Ariceum Therapeutics
Deal Size : $44 million
Deal Type : Acquisition
Ariceum Therapeutics Expands Pipeline with Acquisition of Theragnostics Ltd
Details : The acquisition provides Ariceum with an expanded portfolio of therapeutic and diagnostic assets including, AT-001, a I-123-labelled PARP inhibitor for the treatment of aggressively growing cancers and it has UK ILAP approval for primary and recurrent gl...
Brand Name : ATD-001
Molecule Type : Small molecule
Upfront Cash : $2.5 million
June 01, 2023
Lead Product(s) : ATD-001
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Ariceum Therapeutics
Deal Size : $44 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?
Reset All
